Location: Home > Pharma China Web Edition
  • search
  • go
  • Product/R&D News
  • 2/25/2021Harbour BioMed Announces Chinese IND Approval of for Combo Therapy of ...
  • 2/25/2021China Approves Two More Domestic COVID-19 Vaccines (Free)
  • 2/25/2021AstraZeneca Gains Default Chinese IND Approval for Its Class 1 New Bio...
  • 2/24/2021Gannex Receives U.S. IND Approval for THR-β Agonist ASC41 for NASH
  • 2/18/2021Junshi Bio Announces sNDA Acceptance for Toripalimab Combined with Ch...
  • 2/17/2021BeiGene Announces U.S. FDA Acceptance of sNDA for BRUKINSA (Zanubrutin...
  • 2/9/2021NDA for Amarin's VASCEPA (icosapent ethyl) Accepted in China
  • 2/9/2021Lee's Pharma Announces Breakthrough Therapy Designation of Sorrento's ...
  • 2/8/2021BMS Granted Priority Review for NDA of Luspatercept in China
  • 2/8/2021Sinovac's COVID-19 Vaccine Granted Conditional Approval in China as WH... (Free)
  • 2/3/2021Amgen/Celgene's NDA for Apremilast Accepted in China
  • 2/3/2021Bayer's NDA for Finerenone Accepted in China
  • 2/1/2021Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of...
  • 1/29/2021Ascentage Granted Orphan Drug Designation to Bcl-2 Inhibitor APG-2575 ...
  • 1/28/2021Bio-Thera Files Biologics License Application Avastin Biosimilar with ...
  • 1/28/2021Longyao Pharma Granted Chinese Approval for Clinical Trial of CD20-tar... (Free)
  • 1/26/2021Antengene Granted Chinese IND Approval for ATG-010 (Selinexor) in Co...
  • 1/26/2021EUSA and BeiGene Announce Acceptance of a Biologics License Applicati...
  • 1/22/2021GSK Granted Priority Review for NDA of Two-in-One HIV Drug Juluca in C...
  • 1/22/2021AZ and MSD's Granted Priority Review for New Indication of Lynparza (O...
  • 1/22/2021Everest Medicines Granted Clinical Trial Approval of Sacituzumab Govi...
  • 1/21/2021Jemincare Initiates Phase I Trial of Anti-SARS-Cov-2 Neutralizing Anti...
  • 1/19/2021TRACON Granted Priority Review Acceptance of Envafolimab NDA in Chin...
  • 1/18/2021Kyowa Kirin Granted Conditional Approval of Crysvita (burosumab) in Ch...
  • 1/15/2021Innovent's sNDA for Sintilimab as Second-line Therapy for Squamous NSC...
  • 1/13/2021Gracell Approved to Begin Phase 1/2 Trial of CAR-T GC007g for Leukem...
  • 1/13/2021Sesen Bio and Qilu Pharma Announce Acceptance IND for Vicineum  in C...
  • 1/8/2021Everest Medicines Announces CTA Approval for P3 Trial of Sacituzumab G...
  • 1/8/2021VISEN Pharma Granted IND Approval for P2 Trial of Achondroplasia Drug...
  • 1/5/2021Chipscreen's Chiauranib Granted Breakthrough Therapy Designation in Ch...
  • Page:1/7 Total number of articles:201: [First][<<] [1] [2] [3] [4] [5] [>>] [End]
  • Site map | Contact Us | Links
  • © Wicon International Group